Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.

Grace Therapeutics Inc (GRCE)

Grace Therapeutics Inc (GRCE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Grace Therapeutics to Participate in 16th Annual Craig-Hallum Alpha Select Conference GlobeNewswire - Mon Nov 17, 7:00AM CST

PRINCETON, N.J., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (Nasdaq: GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel,...

GRCE : 3.39 (-2.31%)
Grace Therapeutics Announces Second Quarter 2026 Financial Results, Provides Business Update GlobeNewswire - Thu Nov 13, 7:00AM CST

Announced U.S. Food and Drug Administration (FDA) Acceptance for Review of New Drug Application (NDA) for GTx-104 FDA Established April 23, 2026 as PDUFA Target Date for Review of Submission Seeking...

GRCE : 3.39 (-2.31%)
Grace Therapeutics Announces Abstract Accepted for Presentation at Society of Vascular and Interventional Neurology Annual Meeting GlobeNewswire - Tue Nov 11, 7:30AM CST

PRINCETON, N.J., Nov. 11, 2025 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (Nasdaq: GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel,...

GRCE : 3.39 (-2.31%)
Grace Therapeutics Secures Approximately $4.0 Million through Common Warrant Exercises Following Acceptance of New Drug Application for GTx-104 for formal FDA Review GlobeNewswire - Thu Oct 23, 7:00AM CDT

PRINCETON, N.J., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (Nasdaq: GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel,...

GRCE : 3.39 (-2.31%)
Grace Therapeutics Pivotal Phase 3 STRIVE-ON Safety Trial Presented at 2025 Neurocritical Care Annual Meeting GlobeNewswire - Mon Sep 22, 7:00AM CDT

PRINCETON, N.J., Sept. 22, 2025 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (Nasdaq: GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel,...

GRCE : 3.39 (-2.31%)
Grace Therapeutics Granted Sixth U.S. Patent Covering I.V. Dosing Regimen for GTx-104 GlobeNewswire - Thu Sep 18, 7:30AM CDT

Grant of First Method of Use Patent Adds New Pillar to Grace’s Multi-layered Intellectual Property and Potential Market Exclusivity Protection Patent Coverage Extended to 2043 PRINCETON,...

GRCE : 3.39 (-2.31%)
Grace Therapeutics Announces U.S. Food and Drug Administration Acceptance for Review of New Drug Application for GTx-104 GlobeNewswire - Wed Aug 27, 7:00AM CDT

FDA Establishes April 23, 2026 as PDUFA Target Date for Review of Submission Seeking Approval for GTx-104 in the Treatment of Patients with aneurysmal Subarachnoid Hemorrhage (aSAH) Comprehensive...

GRCE : 3.39 (-2.31%)
Grace Therapeutics Announces First Quarter 2026 Financial Results, Provides Business Update GlobeNewswire - Tue Aug 12, 7:00AM CDT

Submission of New Drug Application (NDA) to U.S. Food and Drug Administration (FDA) for GTx-104   Seeking Approval of GTx-104 in the Treatment of Patients with aneurysmal Subarachnoid Hemorrhage (aSAH)...

GRCE : 3.39 (-2.31%)
Grace Therapeutics Announces Submission of New Drug Application to U.S. Food and Drug Administration for GTx-104 GlobeNewswire - Wed Jun 25, 7:00AM CDT

GRCE : 3.39 (-2.31%)
Grace Therapeutics Announces 2025 Fiscal Year-End Results, Provides Business Update GlobeNewswire - Mon Jun 23, 7:00AM CDT

GRCE : 3.39 (-2.31%)

Barchart Exclusives

Nearly 45% of Its Float Is Being Sold Short. Should You Bet on iRobot Stock Here? Barchart - Wed Dec 10, 3:49PM CST
iRobot stock pushes further up as meme enthusiasts continue to flock into the consumer robots specialist. Here’s why investors are recommended against chasing the rally in IRBT shares. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot